TY - JOUR
T1 - A prognostic score for patients with lower risk myelodysplastic syndrome
AU - Garcia-Manero, G.
AU - Shan, J.
AU - Faderl, S.
AU - Cortes, J.
AU - Ravandi, F.
AU - Borthakur, G.
AU - Wierda, W. G.
AU - Pierce, S.
AU - Estey, E.
AU - Liu, J.
AU - Huang, X.
AU - Kantarjian, H.
N1 - Funding Information:
GG-M is supported in part by a Physician-Scientist Award funded by the Commonwealth Cancer Foundation for Research and a Leukemia and Lymphoma Translational Research Grant no. 6173-07. This work was also supported in part by NCI grant 5P01 CA108631. GG-M designed the study, analyzed data and wrote the manuscript; JS analyzed the data and performed statistical analysis; SF, JC, FR-K, GB, SP, EE analyzed data and helped in the writing of the manuscript; HK analyzed data and wrote the manuscript.
PY - 2008/3
Y1 - 2008/3
N2 - Current prognostic models for myelodysplastic syndromes (MDS) do not allow the identification of patients with lower risk disease and poor prognosis that may benefit from early therapeutic intervention. We evaluated the characteristics of 856 patients with low or intermediate-1 disease by the International Prognostic Scoring System. Mean follow-up was 19.6 months (range 1-262). Of these patients, 87 (10%) transformed to acute myelogenous leukemia, and 429 (50%) had died. By multivariate analysis, characteristics associated with worse survival (P<0.01) were low platelets, anemia, older age, higher percent of marrow blasts and poor-risk cytogenetics. Although not included in the model, higher ferritin (P=0.007) and β2-microglobulin (P<0.001) levels were associated with worse prognosis. This allowed the development of a scoring system in which patients could be grouped in three categories: category 1 (n=182, 21%) with a median survival of 80.3 months (95% CI 68-NA); category 2 (n=408, 48%) with a median survival of 26.6 months (95% CI 22-32) and category 3 (n=265, 31%) with a median survival of 14.2 months (95% CI 13-18). In summary, this analysis indicates that it is possible to identify patients with lower risk MDS and poor prognosis who may benefit from early intervention.
AB - Current prognostic models for myelodysplastic syndromes (MDS) do not allow the identification of patients with lower risk disease and poor prognosis that may benefit from early therapeutic intervention. We evaluated the characteristics of 856 patients with low or intermediate-1 disease by the International Prognostic Scoring System. Mean follow-up was 19.6 months (range 1-262). Of these patients, 87 (10%) transformed to acute myelogenous leukemia, and 429 (50%) had died. By multivariate analysis, characteristics associated with worse survival (P<0.01) were low platelets, anemia, older age, higher percent of marrow blasts and poor-risk cytogenetics. Although not included in the model, higher ferritin (P=0.007) and β2-microglobulin (P<0.001) levels were associated with worse prognosis. This allowed the development of a scoring system in which patients could be grouped in three categories: category 1 (n=182, 21%) with a median survival of 80.3 months (95% CI 68-NA); category 2 (n=408, 48%) with a median survival of 26.6 months (95% CI 22-32) and category 3 (n=265, 31%) with a median survival of 14.2 months (95% CI 13-18). In summary, this analysis indicates that it is possible to identify patients with lower risk MDS and poor prognosis who may benefit from early intervention.
UR - http://www.scopus.com/inward/record.url?scp=40749135870&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=40749135870&partnerID=8YFLogxK
U2 - 10.1038/sj.leu.2405070
DO - 10.1038/sj.leu.2405070
M3 - Article
C2 - 18079733
AN - SCOPUS:40749135870
SN - 0887-6924
VL - 22
SP - 538
EP - 543
JO - Leukemia
JF - Leukemia
IS - 3
ER -